Revolution Medicines Q2 net loss $133M; advances RMC-6236 toward Phase 3 in PDAC

Revolution Medicines, Inc.

2024-Q2 EPS reported -$1.51

Q2 net loss $133.2M vs $98.3M YoY; revenue zero due to Sanofi collaboration termination.
Cash $1.59B; projects funding into 2027; FY 2024 GAAP net loss guidance $560-600M.
RMC-6236 in PDAC: median PFS 8.1 months (KRAS G12X); Phase 3 RASolute 302 planned for 2L this year.
Board appoints Frank Clyburn, former Merck Keytruda leader; new senior hires in medical affairs.
R&D expenses $134.9M vs $98.0M; G&A $21.7M vs $14.6M, driven by clinical and commercial prep.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Frank K. Clyburn, Jr.

Director

RVMD · Revolution Medicines, Inc.

Effective: 2024-08-05
Filed: August 7, 2024, 7:59 PM ET

On August 5, 2024, the board of directors (the “Board”) of the Company increased the authorized size of the Board to ten directors and appointed Frank K. Clyburn, Jr. as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Frank K. Clyburn, Jr. was appointed as Director at Revolution Medicines, Inc..

Action: appointed
Role: Director

Exact text from the filing

On August 5, 2024, the board of directors (the “Board”) of the Company increased the authorized size of the Board to ten directors and appointed Frank K. Clyburn, Jr. as a member of the Board.

View on SEC.gov

Revolution Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-092735

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.